New York, USA, July 21, 2022 (GLOBE NEWSWIRE) -- 60+ Key Companies Actively Working in the Encephalopathy Pipeline Segment | DelveInsight
Encephalopathy refers to dysfunction of the level or contents of consciousness due to brain dysfunction and can result from global brain insults or focal lesions. There are several different types of encephalopathies, and various companies are involved in developing the potential therapies for each type. Some of the major companies developing the therapies in different-stage of development include Xenon Pharmaceuticals, Neurocrine Biosciences, Stoke Therapeutics, Longboard Pharmaceuticals, and Praxis Precision Medicine.
DelveInsight’s 'Encephalopathy Pipeline Insight 2022' report provides comprehensive global coverage of available, marketed, and pipeline encephalopathy therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the encephalopathy pipeline domain.
Key Takeaways from the Encephalopathy Pipeline Report
- DelveInsight’s encephalopathy pipeline report depicts a robust space with 60+ active players working to develop 70+ pipeline therapies for encephalopathy treatment.
- Key encephalopathy companies such as Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, SK Biopharmaceutical, Epygenix Therapeutics, Jazz Pharmaceuticals, Vedanta Biosciences, Versantis, ReAlta Life Sciences, Cosmo Pharmaceuticals, Pharmazz, Umecrine Cognition AB, Neuropathix, DeckTherapeutics, Vittarthaa Life Sciences, Tetra Therapeutics, AC Immune, Brighton Biotech Inc., JCR Pharmaceuticals, Vyant Bio, Inc., Encoded therapeutics, Incannex, Amzell, Bio Pharm Solutions, Anavex Life Sciences, and others are evaluating novel encephalopathy drugs candidate to improve the treatment landscape.
- Promising encephalopathy pipeline therapies in various stages of development include NBI-921352, XEN496, TAK-935, PRAX562, STK001, LP352, KB-3061, PRAX222, SCNA2 LoF ASO, Research programme: DEE13-SCN8A(ASO), AXA 1665, RBX 7455, ETX101, JR-031, Cannabinoid, IHL-216A, ANAVEX 2-73, CMP-SCN, ANAVEX 2-73 and others.
- In June 2022, ReAlta Life Sciences announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to RLS-0071 for treating hypoxic ischemic encephalopathy (HIE). RLS-0071 is the Company’s lead dual action complement inhibitor and innate anti-inflammatory peptide. In March 2022, US FDA cleared an Investigational New Drug (IND) application for a Phase II clinical trial of RLS-0071.
- Lead MRT drug platform product RBX2660 is targeted at treating Clostridium difficile (C.diff), ulcerative colitis, hepatic encephalopathy, and multi-drug resistant organisms. United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 9,433,651 to Rebiotix for its patent application entitled, “Microbiota Restoration Therapy (MRT), Compositions and Methods of Manufacture.” The patent covers Microbiota Restoration Therapy (MRT) compositions and methods for manufacturing, processing, and delivering the compositions and builds on Rebiotix’s patent issuances in Australia and Canada.
- PRAX-562 is the first preferential persistent sodium channel blocker in development to treat a wide range of rare CNS disorders, including rare adult cephalgias and development and epileptic encephalopathy. In April 2021, the US FDA granted orphan drug designation to PRAX-562 for the treatment of SCN2A development and epileptic encephalopathy (SCN2A-DEE), and in January 2021, the US FDA also granted rare pediatric disease designation for PRAX-562 for the treatment of SCN2A-DEE and for the treatment of SCN8A developmental and epileptic encephalopathy (SCN8A-DEE).
- In August 2021, Vyant Bio, Inc., and Cyclica, Inc., announced a non-exclusive strategic collaboration combining Vyant Bio’s patient-derived complex organoid biology alongside Cyclica’s proteome-wide, Artificial Intelligence (“AI”) enabled discovery platform to identify new treatments for CDKL5 Deficiency Disorder (“CDD”), a severe neurodevelopmental epilepsy disorder with no effective treatments or cure.
Request a sample and discover the recent advances in encephalopathy treatment drugs @ Encephalopathy Pipeline Outlook
The encephalopathy pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage encephalopathy products, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the encephalopathy pipeline landscape.
Encephalopathy Overview
Encephalopathy is a broad term that refers to abnormal brain function or structure. The irregularity could be temporary, recurring, or permanent. Brain function loss can be reversible, static and steady, or progressive, with a progressive decrease of brain activity over time. Encephalopathy is classified into two types: reversible and irreversible.
The encephalopathy symptoms vary depending on the type and cause, but some of the most prevalent are confusion, memory loss, personality changes, and difficulty thinking clearly or focusing. Some people will also experience: difficulty speaking, muscle weakness or twitches, uncontrollable eye movements, tremors, and difficulty swallowing. The history provided by the patient, family, or friends is used to make an encephalopathy diagnosis. Based on the encephalopathy symptoms, the health care provider will have a better grasp of the various encephalopathy causes.
Depending on the clinical condition, imaging examinations such as X-rays, computed tomography (CT), and magnetic resonance imaging (MRI) may be relevant. Lumbar puncture (spinal tap) may be useful in detecting infection, bleeding, and inflammation. In addition, aberrant proteins, chemicals, and cells can be detected in cerebrospinal fluid. Patients with known recurring encephalopathy may be eligible for home encephalopathy treatment programs.
Find out more about encephalopathy drugs @ Encephalopathy Treatment Drugs
A snapshot of the Encephalopathy Pipeline Drugs mentioned in the report:
| Drugs | Company | Phase | MoA | RoA |
| XEN496 | Xenon Pharmaceuticals | Phase III | GABA A receptor agonists; KCNQ potassium channel agonists | Oral |
| AXA 1665 | Axcella Health | Phase II | Metabolism-modulators | Oral |
| RBX 7455 | Rebiotix | Phase II | Bacteria replacements; Gastrointestinal microbiome modulators | Oral |
| NBI-921352 | Neurocrine Biosciences | Phase II | Nav1.6 voltage-gated sodium channel inhibitors | Oral |
| STK-001 | Stoke Therapeutics | Phase II | NAV1.1 voltage-gated sodium channel modulators; RNA interference | Intrathecal |
| LP352 | Longboard Pharmaceuticals | Phase I/II | Serotonin 2C receptor agonists | Oral |
| KB-3061 | Knopp Bioscience | Preclinical | KCNQ2 potassium channel stimulants | Oral |
Learn more about the novel and emerging encephalopathy pipeline therapies @ Encephalopathy Clinical Trials
Encephalopathy Therapeutics Assessment
The encephalopathy pipeline report proffers an integral view of the encephalopathy emerging novel therapies segmented by stage, product type, molecule type, mechanism of action, and route of administration.
Scope of the Encephalopathy Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Ophthalmic, Oral, Parenteral, Subcutaneous, Topical, Transdermal
- Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
- Therapeutics Assessment By Mechanism of Action: GABA A receptor agonists, KCNQ potassium channel agonists, Metabolism-modulators, Bacteria replacements, Gastrointestinal microbiome modulators, Nav1.6 voltage-gated sodium channel inhibitors, Cholesterol 24-hydroxylase inhibitors, NMDA receptor modulators, Sodium channel antagonists
- Key Encephalopathy Companies: Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, SK Biopharmaceutical, Epygenix Therapeutics, Jazz Pharmaceuticals, Vedanta Biosciences, Versantis, ReAlta Life Sciences, Cosmo Pharmaceuticals, Pharmazz, Umecrine Cognition AB, Neuropathix, DeckTherapeutics, Vittarthaa Life Sciences, Tetra Therapeutics, AC Immune, Brighton Biotech Inc., JCR Pharmaceuticals, Vyant Bio, Inc., Encoded therapeutics, Incannex, Amzell, Bio Pharm Solutions, Anavex Life Sciences and others
- Key Encephalopathy Pipeline Therapies: NBI-921352, XEN496, TAK-935, PRAX562, STK001, LP352, KB-3061, PRAX222, SCNA2 LoF ASO, Research programme: DEE13-SCN8A(ASO), AXA 1665, RBX 7455, ETX101, JR-031, Cannabinoid, IHL-216A, ANAVEX 2-73, CMP-SCN, ANAVEX 2-73 and others.
Dive deep into rich insights for drugs for encephalopathy treatment, visit @ Encephalopathy Treatment
Table of Contents
| 1. | Encephalopathy Pipeline Report Introduction |
| 2. | Encephalopathy Pipeline Report Executive Summary |
| 3. | Encephalopathy Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Encephalopathy Pipeline Therapeutics |
| 6. | Encephalopathy Pipeline: Late Stage Products (Pre-registration) |
| 7. | Encephalopathy Pipeline: Late Stage Products (Phase III) |
| 7.1 | XEN496: Xenon Pharmaceuticals |
| 8. | Encephalopathy Pipeline: Mid Stage Products (Phase II) |
| 8.1 | AXA 1665: Axcella Health |
| 9. | Encephalopathy Pipeline: Early Stage Products (Phase I/II) |
| 9.1 | LP352: Longboard Pharmaceuticals |
| 10. | Encephalopathy Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Encephalopathy Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Encephalopathy Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the encephalopathy pipeline therapeutics, reach out @ Encephalopathy Drugs
Related Reports
Developmental and Epileptic Encephalopathies Market
Developmental and Epileptic Encephalopathies Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key developmental and epileptic encephalopathies companies including Novartis, Roche, Lundbeck, among others.
Developmental and Epileptic Encephalopathies Epidemiology Forecast
Developmental and Epileptic Encephalopathies Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical and forecasted developmental and epileptic encephalopathies epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Developmental and Epileptic Encephalopathies Pipeline
Developmental and Epileptic Encephalopathies Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key developmental and epileptic encephalopathies companies, including Novartis, Roche, Lundbeck, among others.
Hepatic Encephalopathy Pipeline
Hepatic Encephalopathy Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hepatic encephalopathy companies, including Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, among others.
Overt Hepatic Encephalopathy Pipeline
Overt Hepatic Encephalopathy Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key overt hepatic encephalopathy companies, including Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, among others.
Chronic Traumatic Encephalopathy Pipeline
Chronic Traumatic Encephalopathy Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key chronic traumatic encephalopathy companies, including Tetra Therapeutics, Brighton Biotech, among others.
Other Trending Reports
Persistent Depressive Disorder Market | Gene Therapy for Ocular Rare Disease Market | Congestive Heart Failure Market | CRISPR Therapies Pipeline | Desmoplastic Small Round Cell Tumors Market | India Healthcare Outlook Report | Psychosis Market | Dental Lasers Market | Primary Immune Deficiency Market I Dyslipidemia Market | Lateral Epicondylitis Disease Market | Castration-Resistant Prostate Cancer Market | Metrorrhagia Market | Global Messenger RNA-based Vaccines and Therapeutics Market | Negative Pressure Wound Therapy Systems Market | US Healthcare Outlook Report | Mucinous Cystic Neoplasms Market | Hot Flashes Market | Varicose Veins - Market | Hemostats Market | Injectable Drug Delivery Devices Market | Breast Pumps Market | Physiotherapy Equipment Market | Trastuzumab Biosimilars Insight | Deep Brain Stimulation Devices Market | Retinoblastoma Market | Venous Stenosis Market | Tumor Ablation Market | Substance Abuse Market | Insulin Glargine Biosimilar Insight | Interspinous Spacers Market | Anti-hypertension Market
Related Healthcare Blogs
Developmental and Epileptic Encephalopathies Treatment Pipeline
Epidiolex vs Fintepla
Hepatic Encephalopathy Market Dynamics
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences.
Connect with us at LinkedIn
